Subtype
Malignant Peritoneal Neoplasm
CI-CAN-00001164Explore in graph →
124 active trials5 approved drugs
- NCIt
- C3538
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001164Explore in graph →
Clinical trials
502 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (75)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01097746 | First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer | completed | Phase 2 | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT04368130 | SIGNAL:Identifying Behavioral Anomalies Using Smartphones to Improve Cancer Care(SIGNAL) | withdrawn | N/A | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 14, 2022 |
| clinicaltrials |
| NCT05537844 | Longitudinal Sample Collection to Investigate Adaptation and Evolution of Ovarian High-grade Serous Carcinoma(BriTROC-2) | unknown | — | 250 | Liz-Anne LewsleyOTHER | 1 | Sep 23, 2022 | clinicaltrials |
| NCT02788708 | Lenvatinib and Weekly Paclitaxel for Patients With Recurrent Endometrial or Ovarian Cancer | completed | Phase 1 | 26 | Floor BackesOTHER | 1 | Sep 19, 2022 | clinicaltrials |
| NCT02865811 | Pembrolizumab Combined With PLD For Recurrent Platinum Resistant Ovarian, Fallopian Tube Or Peritoneal Cancer | completed | Phase 2 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT05043402 | A Study of Navicixizumab in Patients With Platinum Resistant Ovarian Cancer | unknown | Phase 3 | 400 | OncXerna Theraputics, Inc.INDUSTRY | 0 | Aug 15, 2022 | clinicaltrials |
| NCT03604653 | Trial of Cytoreductive Surgery and HIPEC in Patients With Primary and Secondary Peritoneal Cancers | completed | — | 10 | Holy Name Medical Center, Inc.OTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT03029598 | Pembrolizumab and Carboplatin in Treating Patients With Relapsed or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 29 | University of WashingtonOTHER | 1 | Jul 26, 2022 | clinicaltrials |
| NCT03023319 | Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors | completed | Phase 1 | 6 | Nagla Abdel KarimOTHER | 1 | Jun 14, 2022 | clinicaltrials |
| NCT01591772 | Structural and Functional Imaging and Cognitive Functions in Ovarian Cancer | completed | — | 36 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 1, 2022 | clinicaltrials |
| NCT04088786 | Phase I Trial HIPEC With Nal-irinotecan | completed | Phase 1 | 18 | Stony Brook UniversityOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT05353582 | Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases | unknown | Phase 2 | 168 | Sun Yat-sen UniversityOTHER | 1 | Apr 29, 2022 | clinicaltrials |
| NCT02033616 | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas | unknown | Phase 2 | 99 | Aivita Biomedical, Inc.INDUSTRY | 1 | Apr 25, 2022 | clinicaltrials |
| NCT04229615 | A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy | unknown | Phase 3 | 690 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Apr 25, 2022 | clinicaltrials |
| NCT03924245 | Olaparib and Entinostat in Patients With Recurrent, Platinum-Refractory, Resistant Ovarian, Primary Peritoneal, Fallopian Tube Cancers | terminated | Phase 1 | 3 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT03983226 | Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) | recruiting | Phase 2 | 167 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Mar 18, 2022 | clinicaltrials |
| NCT03976973 | BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei | unknown | Phase 2 | 62 | Mucpharm Pty LtdINDUSTRY | 0 | Mar 15, 2022 | clinicaltrials |
| NCT03378128 | Debulking Surgery in Ovarian Cancer(MIID-SOC) | completed | N/A | 50 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 14, 2022 | clinicaltrials |
| NCT02316834 | Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(POSITION) | completed | Early Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Feb 24, 2022 | clinicaltrials |
| NCT02824328 | A Pilot Study Investigating the Effect of Chemotherapy on the Tumoral Immunoprofile of Gynecologic Cancers | completed | — | 47 | Duke UniversityOTHER | 1 | Feb 11, 2022 | clinicaltrials |
| NCT00096200 | Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Feb 8, 2022 | clinicaltrials |
| NCT00886691 | Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 150 | GOG FoundationNETWORK | 1 | Feb 4, 2022 | clinicaltrials |
| NCT01166737 | Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer(DESKTOPIII) | completed | N/A | 408 | AGO Study GroupOTHER | 12 | Jan 25, 2022 | clinicaltrials |
| NCT05193006 | Assessment of Histologic Prognostic Factors in Peritoneal Malignant Mesothelioma | unknown | — | 300 | Hospices Civils de LyonOTHER | 6 | Jan 14, 2022 | clinicaltrials |
| NCT04375956 | Study on Pembrolizumab in Recurrent, Platinum Resistant, CPS >1 Positive Ovarian, Fallopian Tube and Primary Peritoneal Cancer Patients(MITO 27) | unknown | Phase 2 | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Dec 20, 2021 | clinicaltrials |
| NCT02315469 | Comprehensive Patient Questionnaires in Predicting Complications in Older Patients With Gynecologic Cancer Undergoing Surgery | completed | — | 190 | NRG OncologyOTHER | 2 | Nov 24, 2021 | clinicaltrials |
| NCT02657928 | Ribociclib and Letrozole in Treating Patients With Relapsed ER Positive Ovarian, Fallopian Tube, Primary Peritoneal, or Endometrial Cancer | completed | Phase 2 | 40 | Mayo ClinicOTHER | 1 | Oct 26, 2021 | clinicaltrials |
| NCT00888615 | Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer | completed | Phase 2 | 58 | GOG FoundationNETWORK | 1 | Oct 20, 2021 | clinicaltrials |
| NCT00989651 | Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 | 431 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2021 | clinicaltrials |
| NCT01720173 | Dalantercept in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer | completed | Phase 2 | 30 | Gynecologic Oncology GroupNETWORK | 1 | Oct 20, 2021 | clinicaltrials |
| NCT02853318 | Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 2 | 40 | Roswell Park Cancer InstituteOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT03297489 | Intravital Microscopy in Evaluating Patients With Primary Peritoneal, Fallopian Tube, or Stage IA-IV Ovarian Cancer | completed | Early Phase 1 | 19 | Roswell Park Cancer InstituteOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT00108745 | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer | unknown | Phase 3 | 1,157 | GOG FoundationNETWORK | 1 | Sep 30, 2021 | clinicaltrials |
| NCT00954174 | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer | unknown | Phase 3 | 637 | GOG FoundationNETWORK | 2 | Sep 30, 2021 | clinicaltrials |
| NCT03607955 | Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Sep 29, 2021 | clinicaltrials |
| NCT03608618 | Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal Mesothelioma | terminated | Phase 1 | 14 | MaxCyte, Inc.INDUSTRY | 1 | Sep 5, 2021 | clinicaltrials |
| NCT03685695 | Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 9 | Roswell Park Cancer InstituteOTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT04537702 | Prospective Randomized Trial of Streamlined Genetic Education and Testing for Ovarian Cancer Patients | completed | N/A | 64 | Duke UniversityOTHER | 1 | Aug 26, 2021 | clinicaltrials |
| NCT04983550 | Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC | unknown | Phase 2 | 126 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Jul 30, 2021 | clinicaltrials |
| NCT02785250 | Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer | unknown | Phase 1 / Phase 2 | 85 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Jun 18, 2021 | clinicaltrials |
| NCT03332576 | Phase 1b Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer | completed | Phase 1 | 37 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Jun 18, 2021 | clinicaltrials |
| NCT01611766 | Surgery or Chemotherapy in Recurrent Ovarian Cancer (SOC 1 Trial)? | unknown | Phase 3 | 356 | Shanghai Gynecologic Oncology GroupOTHER_GOV | 1 | Jun 10, 2021 | clinicaltrials |
| NCT03211806 | Detecting Activity to Support Healing(DASH) | completed | N/A | 26 | University of PittsburghOTHER | 1 | May 24, 2021 | clinicaltrials |
| NCT00582205 | Feasibility Trial of Intraperitoneal Chemotherapy for Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma | terminated | Phase 2 | 21 | University of OklahomaOTHER | 1 | May 19, 2021 | clinicaltrials |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | withdrawn | Phase 1 | 0 | Pamela MunsterOTHER | 0 | May 18, 2021 | clinicaltrials |
| NCT04834544 | A Study of Maintenance DCVAC/OvCa After First-line Chemotherapy Added Standard of Care | recruiting | Phase 2 | 75 | Peking University Third HospitalOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT01065662 | AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies | completed | Phase 1 | 11 | Susana M. Campos, MDOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT04846842 | A Study of Oral Gimatecan in Platinum-Resistant Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer | unknown | Phase 2 | 46 | Lee's Pharmaceutical LimitedINDUSTRY | 0 | Apr 19, 2021 | clinicaltrials |
| NCT02485990 | Study of Tremelimumab Alone or Combined With Olaparib for Patients With Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma) | terminated | Phase 1 | 24 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 12, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Oct 28, 2022source: clinicaltrials